Shots: The P-III HLX04-mCRC03 study involve assessing of HLX04 (7.5mg/kg, q3w, when combined with XELOX or 5mg/kg, q2w when combined with mFOLFOX6) vs reference bevacizumab + CT (XELOX or mFOLFOX6) […]readmore
Tags : Released
The submission of the application and labelling for proposed biosimilar or proposed interchangeable biosimilar for fewer than all the reference product’s licensed condition of use The submission of supplement to […]readmore
Biosimilars
Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines
The new updated guidelines are being built on previous recommendations based on best practices for imaging, managing biologic and biosimilars usage in patients, and providing information on new medication The […]readmore